Hybrid closed-loop insulin therapy improved glycemic control in adolescents and young adults with type 1 diabetes. These outcomes, derived from the International Diabetes Closed-Loop (iDCL) Trial, are reported in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT).